<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433613</url>
  </required_header>
  <id_info>
    <org_study_id>GOLD AF</org_study_id>
    <nct_id>NCT02433613</nct_id>
  </id_info>
  <brief_title>Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)</brief_title>
  <official_title>Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IHF GmbH - Institut f√ºr Herzinfarktforschung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, single-arm, non-interventional and open-label registry. The
      purpose of the registry is to document use of Phased Radio Frequency Ablation (RFA)
      (hereafter &quot;Phased RFA&quot;) System in a real world patient population with atrial fibrillation
      (AF) and evaluate its performance.

      Gold AF will enroll a minimum of 1,000 patients who undergo Phased RFA in approximately 38
      sites in Western, Central Europe, Israel and South Korea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry will collect data prospectively on patients with paroxysmal, persistent and
      longstanding persistent atrial fibrillation (hereafter &quot;AF&quot;) undergoing Phased RFA treatment.
      Phased RFA will be applied according to the 'Intended Use' in CE mark (European Conformity)
      release and product packaging.

      The treatment will be performed according to routine hospital practice and no additional
      tests are required specific to the registry. This registry will serve as a tool to collect
      clinical data in order to expand the knowledge base of safety, effectiveness and
      functionality of the Medtronic Phased RFA System in a real world patient population.

      The key measures collected for the patients will be inclusive of, but are not limited to,
      clinical data pertaining to AF and individual disease state(s) characterized by form of AF
      and underline diseases, Phased RFA procedure details including timing and catheters in use,
      procedure and system related adverse events, AF recurrence, re-ablations and left atrial
      flutter rate after the index Phased RFA procedure. Additionally, this study will provide
      further information in the evolving anticoagulation strategies (e.g. continuous versus
      bridging and vitamin K antagonist versus novel oral anticoagulants) in the setting of AF
      ablations. Patients will be followed minimum for 12 months and maximum for 14 months after
      the Phased RFA ablation procedure. The twelve month follow-up can be done by telephone if it
      is not standard of care in the hospital's practice. During the twelve month follow-up
      patients will be interviewed with a quality of life questionnaire and results will be
      compared to the quality of life questionaire completed before the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">November 20, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Estimate Phased RFA (Radio Frequency Ablation) Mid-term Success Rate</measure>
    <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
    <description>Success rate will be estimated as time to first event: AF recurrence and/or left Atrial Flutter. Parameters of interest include: re-ablations, ECG/EGM (electrogram) recorded AF, electrical and pharmacological cardioversions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate Phased RFA Mid-term Safety</measure>
    <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
    <description>Estimate major procedure/system related complications of Phased RFA</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute Procedural Success Rate</measure>
    <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
    <description>Procedure considered successful if all PVs (pulmonary veins) were isolated (entrance and/or exit block confirmation per vein) and procedure was not declined due to technical issues related to Phased RFA system</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedural Efficiency - Procedure Duration, Laboratory Occupancy Duration and Fluoroscopy Time</measure>
    <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
    <description>Parameters to measure the efficiency: procedure duration, laboratory occupancy duration, fluoroscopy time</description>
  </other_outcome>
  <other_outcome>
    <measure>Peri-procedural Anticoagulation Therapy - Activated Clotting Time</measure>
    <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
    <description>Characterize anticoagulation therapy: activated clotting time (ACT) during the procedure. Correlate anticoagulation therapy with thromboembolic events and bleeding the peri -procedural thromboembolic events and bleeding</description>
  </other_outcome>
  <other_outcome>
    <measure>Single Catheter PVAC (Pulmonary Vein Ablation Catheter) GOLD Utilization in Persistent AF Ablation - Phased RFA Catheters Used</measure>
    <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
    <description>Evaluate which tools participating centers use (MAAC (Multi-Array Ablation Catheter) and/or MASC (Multi-Array Septal Catheter) and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Dynamic - AFEQT Score at 12 Months</measure>
    <time_frame>Patient will be followed for minimum 12 months, maximum 14 months, 12 month reported</time_frame>
    <description>Quality of life will be captured using the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. It is a standardized, disease-specific, reliable and responsive measure of health-related quality of life in subjects with AF. The AFEQT is a self-reported questionnaire with responses on a 7-point Likert scale. The 20-item instrument is divided into three domains (4-item symptom score, 8-item daily activities score, 6-item treatment concerns score) plus two treatment satisfaction questions.In countries where no validated version is available yet (e.g. Israel, Portugal), the AFEQT questionnaire will not be applied or will be additionally validated for the country official languages according to local requirements and regulations.
Overall or subscale range from 0 to 100. A score of 0 corresponds to complete disability (or responding &quot;extremely&quot; limited, difficult or bothersome to all questions answered), while a score of 100 corresponds to no disability).</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedural Efficiency - Number of Catheters Used</measure>
    <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
    <description>Parameters to measure the efficiency: Phased RFA consumables used</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedural Efficiency - Number of Adjunctive Devices Used</measure>
    <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
    <description>Parameters to measure the efficiency: adjunctive devices used</description>
  </other_outcome>
  <other_outcome>
    <measure>Peri-procedural Anticoagulation Therapy - International Normalized Ratio (INR)</measure>
    <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
    <description>Characterize anticoagulation therapy: international normalized ratio (INR). Correlate anticoagulation therapy with thromboembolic events and bleeding the peri -procedural thromboembolic events and bleeding. The INR is derived from prothrombin time (PT) which is calculated as a ratio of the patient's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the World Health Organization (WHO) using the following formula: INR = Patient PT √∑ Control PT. INR can be used to assess the risk of bleeding or the coagulation status of the patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>Peri-procedural Anticoagulation Therapy - Percent of Participants With Previous and Peri-Procedural Anticoagulation Therapy</measure>
    <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
    <description>Characterize anticoagulation therapy: utilization of vitamin K antagonists (VKA), novel oral anticoagulants (NOAC), peri -procedural &quot;bridging&quot; vs &quot;no bridging&quot; strategy. Correlate anticoagulation therapy with thromboembolic events and bleeding the peri -procedural thromboembolic events and bleeding</description>
  </other_outcome>
  <other_outcome>
    <measure>Single Catheter PVAC (Pulmonary Vein Ablation Catheter) GOLD Utilization in Persistent AF Ablation - Number Total Cardioversions</measure>
    <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
    <description>Evaluate which tools participating centers use (MAAC (Multi-Array Ablation Catheter) and/or MASC (Multi-Array Septal Catheter) and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
  </other_outcome>
  <other_outcome>
    <measure>Single Catheter PVAC (Pulmonary Vein Ablation Catheter) GOLD Utilization in Persistent AF Ablation - Percentage of Persistent AF Participants With Cardioversions for AF Within Last 12 Months</measure>
    <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
    <description>Evaluate which tools participating centers use (MAAC (Multi-Array Ablation Catheter) and/or MASC (Multi-Array Septal Catheter) and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
  </other_outcome>
  <other_outcome>
    <measure>Single Catheter PVAC (Pulmonary Vein Ablation Catheter) GOLD Utilization in Persistent AF Ablation - Percentage of Catheters Used Per Participant Procedure</measure>
    <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
    <description>Evaluate which tools participating centers use (MAAC (Multi-Array Ablation Catheter) and/or MASC (Multi-Array Septal Catheter) and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
  </other_outcome>
  <enrollment type="Actual">1071</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible are all patients with paroxysmal, persistent and long-standing persistent AF who
        fulfill all inclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient with AF who is scheduled for Phased RFA procedure

          -  Patient signed patient informed consent or patient data release form

          -  Age ‚â•18 years old To avoid enrollment bias in this cohort of patient and reflect &quot;real
             world&quot; clinical practice for Phased RFA no exclusion criteria will be defined.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucas Boersma, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonious</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meleze Hocini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H√¥pital Cardiologique du Haut-L√©v√™que</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMC Parly 2</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Cardiologique du Nord</name>
      <address>
        <city>Saint-Denis</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jo Ann Medical Center</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus</name>
      <address>
        <city>D√ºsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gef√§√üzentrum Oberallg√§u-Kempten</name>
      <address>
        <city>Kempten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum M√ºnster</name>
      <address>
        <city>M√ºnster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz-Krankenhaus Paderborn</name>
      <address>
        <city>Paderborn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Alexandra</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Hospital</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Barzilai Medical Center Ashkleon</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osped. Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mater Salutis</name>
      <address>
        <city>Legnago</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Osped. S.Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. San Camillo Forlanini</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sejong General Hospital</name>
      <address>
        <city>Bucheon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden B.V.</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 4</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 2</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 Wojskowy Szpital Kliniczny</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Notre - Hospital de Santa Maria E.P.E.</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>Donostia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik St. Anna AG</name>
      <address>
        <city>Z√ºrich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastbourne District General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <results_first_submitted>March 29, 2020</results_first_submitted>
  <results_first_submitted_qc>April 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2020</results_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Vein Isolation</keyword>
  <keyword>Phased Radiofrequency Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02433613/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 25, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02433613/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phased RFA System</title>
          <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP (electrophysiology) laboratories utilizing the Phased AF system was collected.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1071"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1054"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phased RFA System</title>
          <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1054"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-Mass-Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atrial Fibrillation (AF) Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Paroxysmal Atrial Fibrillation (PAF)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="740"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Persistent Atrial Fibrillation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="279"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Longstanding persistent Atrial Fibrillation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptomatic Atrial Fibrillation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimate Phased RFA (Radio Frequency Ablation) Mid-term Success Rate</title>
        <description>Success rate will be estimated as time to first event: AF recurrence and/or left Atrial Flutter. Parameters of interest include: re-ablations, ECG/EGM (electrogram) recorded AF, electrical and pharmacological cardioversions.</description>
        <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate Phased RFA (Radio Frequency Ablation) Mid-term Success Rate</title>
          <description>Success rate will be estimated as time to first event: AF recurrence and/or left Atrial Flutter. Parameters of interest include: re-ablations, ECG/EGM (electrogram) recorded AF, electrical and pharmacological cardioversions.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.1" spread="76.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimate Phased RFA Mid-term Safety</title>
        <description>Estimate major procedure/system related complications of Phased RFA</description>
        <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate Phased RFA Mid-term Safety</title>
          <description>Estimate major procedure/system related complications of Phased RFA</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Acute Procedural Success Rate</title>
        <description>Procedure considered successful if all PVs (pulmonary veins) were isolated (entrance and/or exit block confirmation per vein) and procedure was not declined due to technical issues related to Phased RFA system</description>
        <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Procedural Success Rate</title>
          <description>Procedure considered successful if all PVs (pulmonary veins) were isolated (entrance and/or exit block confirmation per vein) and procedure was not declined due to technical issues related to Phased RFA system</description>
          <units>% of procedural success rate</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1036"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Procedural Efficiency - Procedure Duration, Laboratory Occupancy Duration and Fluoroscopy Time</title>
        <description>Parameters to measure the efficiency: procedure duration, laboratory occupancy duration, fluoroscopy time</description>
        <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Efficiency - Procedure Duration, Laboratory Occupancy Duration and Fluoroscopy Time</title>
          <description>Parameters to measure the efficiency: procedure duration, laboratory occupancy duration, fluoroscopy time</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1048"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Procedure Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.0" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of PVAC ablation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0" spread="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time from delivery to cathlab to 3D Mapping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.1" spread="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cathlab Occupancy Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.7" spread="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Fluoroscopy Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peri-procedural Anticoagulation Therapy - Activated Clotting Time</title>
        <description>Characterize anticoagulation therapy: activated clotting time (ACT) during the procedure. Correlate anticoagulation therapy with thromboembolic events and bleeding the peri -procedural thromboembolic events and bleeding</description>
        <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Peri-procedural Anticoagulation Therapy - Activated Clotting Time</title>
          <description>Characterize anticoagulation therapy: activated clotting time (ACT) during the procedure. Correlate anticoagulation therapy with thromboembolic events and bleeding the peri -procedural thromboembolic events and bleeding</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Highest activated clotting time (ACT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356.9" spread="115.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lowest ACT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274.4" spread="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Single Catheter PVAC (Pulmonary Vein Ablation Catheter) GOLD Utilization in Persistent AF Ablation - Phased RFA Catheters Used</title>
        <description>Evaluate which tools participating centers use (MAAC (Multi-Array Ablation Catheter) and/or MASC (Multi-Array Septal Catheter) and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
        <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
        <population>Patients with persistent AF only</population>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Catheter PVAC (Pulmonary Vein Ablation Catheter) GOLD Utilization in Persistent AF Ablation - Phased RFA Catheters Used</title>
          <description>Evaluate which tools participating centers use (MAAC (Multi-Array Ablation Catheter) and/or MASC (Multi-Array Septal Catheter) and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
          <population>Patients with persistent AF only</population>
          <units>catheter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quality of Life Dynamic - AFEQT Score at 12 Months</title>
        <description>Quality of life will be captured using the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. It is a standardized, disease-specific, reliable and responsive measure of health-related quality of life in subjects with AF. The AFEQT is a self-reported questionnaire with responses on a 7-point Likert scale. The 20-item instrument is divided into three domains (4-item symptom score, 8-item daily activities score, 6-item treatment concerns score) plus two treatment satisfaction questions.In countries where no validated version is available yet (e.g. Israel, Portugal), the AFEQT questionnaire will not be applied or will be additionally validated for the country official languages according to local requirements and regulations.
Overall or subscale range from 0 to 100. A score of 0 corresponds to complete disability (or responding &quot;extremely&quot; limited, difficult or bothersome to all questions answered), while a score of 100 corresponds to no disability).</description>
        <time_frame>Patient will be followed for minimum 12 months, maximum 14 months, 12 month reported</time_frame>
        <population>911 patients filled in validated language versions of the AFEQT; 143 patients filled in not validated language versions; AFEQT score at baseline available for 954 patients. The response on the AFEQT are scored on a 1 to 7 Likert scale, 1 = &quot;not at all&quot; to 7 = &quot;Extremely&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Dynamic - AFEQT Score at 12 Months</title>
          <description>Quality of life will be captured using the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. It is a standardized, disease-specific, reliable and responsive measure of health-related quality of life in subjects with AF. The AFEQT is a self-reported questionnaire with responses on a 7-point Likert scale. The 20-item instrument is divided into three domains (4-item symptom score, 8-item daily activities score, 6-item treatment concerns score) plus two treatment satisfaction questions.In countries where no validated version is available yet (e.g. Israel, Portugal), the AFEQT questionnaire will not be applied or will be additionally validated for the country official languages according to local requirements and regulations.
Overall or subscale range from 0 to 100. A score of 0 corresponds to complete disability (or responding &quot;extremely&quot; limited, difficult or bothersome to all questions answered), while a score of 100 corresponds to no disability).</description>
          <population>911 patients filled in validated language versions of the AFEQT; 143 patients filled in not validated language versions; AFEQT score at baseline available for 954 patients. The response on the AFEQT are scored on a 1 to 7 Likert scale, 1 = &quot;not at all&quot; to 7 = &quot;Extremely&quot;.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AFEQT Score at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="954"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AFEQT Score at 12 Months Follow-Up (site visit)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AFEQT Score at 12 Months Follow-Up (phone call)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="499"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes in QoL Score Baseline to 12 M FU (visit)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes in QoL Score Baseline to 12 M FU (phone)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Procedural Efficiency - Number of Catheters Used</title>
        <description>Parameters to measure the efficiency: Phased RFA consumables used</description>
        <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Efficiency - Number of Catheters Used</title>
          <description>Parameters to measure the efficiency: Phased RFA consumables used</description>
          <units>catheters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1048"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Procedural Efficiency - Number of Adjunctive Devices Used</title>
        <description>Parameters to measure the efficiency: adjunctive devices used</description>
        <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Efficiency - Number of Adjunctive Devices Used</title>
          <description>Parameters to measure the efficiency: adjunctive devices used</description>
          <units>procedures</units>
          <param>Number</param>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1048"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peri-procedural Anticoagulation Therapy - International Normalized Ratio (INR)</title>
        <description>Characterize anticoagulation therapy: international normalized ratio (INR). Correlate anticoagulation therapy with thromboembolic events and bleeding the peri -procedural thromboembolic events and bleeding. The INR is derived from prothrombin time (PT) which is calculated as a ratio of the patient's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the World Health Organization (WHO) using the following formula: INR = Patient PT √∑ Control PT. INR can be used to assess the risk of bleeding or the coagulation status of the patients.</description>
        <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Peri-procedural Anticoagulation Therapy - International Normalized Ratio (INR)</title>
          <description>Characterize anticoagulation therapy: international normalized ratio (INR). Correlate anticoagulation therapy with thromboembolic events and bleeding the peri -procedural thromboembolic events and bleeding. The INR is derived from prothrombin time (PT) which is calculated as a ratio of the patient's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the World Health Organization (WHO) using the following formula: INR = Patient PT √∑ Control PT. INR can be used to assess the risk of bleeding or the coagulation status of the patients.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peri-procedural Anticoagulation Therapy - Percent of Participants With Previous and Peri-Procedural Anticoagulation Therapy</title>
        <description>Characterize anticoagulation therapy: utilization of vitamin K antagonists (VKA), novel oral anticoagulants (NOAC), peri -procedural &quot;bridging&quot; vs &quot;no bridging&quot; strategy. Correlate anticoagulation therapy with thromboembolic events and bleeding the peri -procedural thromboembolic events and bleeding</description>
        <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Peri-procedural Anticoagulation Therapy - Percent of Participants With Previous and Peri-Procedural Anticoagulation Therapy</title>
          <description>Characterize anticoagulation therapy: utilization of vitamin K antagonists (VKA), novel oral anticoagulants (NOAC), peri -procedural &quot;bridging&quot; vs &quot;no bridging&quot; strategy. Correlate anticoagulation therapy with thromboembolic events and bleeding the peri -procedural thromboembolic events and bleeding</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oral anticoagulants discontinued before procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previously treated with VKA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previously treated with NOACs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major procedure related event (stroke)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Single Catheter PVAC (Pulmonary Vein Ablation Catheter) GOLD Utilization in Persistent AF Ablation - Number Total Cardioversions</title>
        <description>Evaluate which tools participating centers use (MAAC (Multi-Array Ablation Catheter) and/or MASC (Multi-Array Septal Catheter) and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
        <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
        <population>Patients with persistent AF only</population>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Catheter PVAC (Pulmonary Vein Ablation Catheter) GOLD Utilization in Persistent AF Ablation - Number Total Cardioversions</title>
          <description>Evaluate which tools participating centers use (MAAC (Multi-Array Ablation Catheter) and/or MASC (Multi-Array Septal Catheter) and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
          <population>Patients with persistent AF only</population>
          <units>cardioversions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Single Catheter PVAC (Pulmonary Vein Ablation Catheter) GOLD Utilization in Persistent AF Ablation - Percentage of Persistent AF Participants With Cardioversions for AF Within Last 12 Months</title>
        <description>Evaluate which tools participating centers use (MAAC (Multi-Array Ablation Catheter) and/or MASC (Multi-Array Septal Catheter) and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
        <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
        <population>Patients with persistent AF only</population>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Catheter PVAC (Pulmonary Vein Ablation Catheter) GOLD Utilization in Persistent AF Ablation - Percentage of Persistent AF Participants With Cardioversions for AF Within Last 12 Months</title>
          <description>Evaluate which tools participating centers use (MAAC (Multi-Array Ablation Catheter) and/or MASC (Multi-Array Septal Catheter) and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
          <population>Patients with persistent AF only</population>
          <units>percentage of persistent AF patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Single Catheter PVAC (Pulmonary Vein Ablation Catheter) GOLD Utilization in Persistent AF Ablation - Percentage of Catheters Used Per Participant Procedure</title>
        <description>Evaluate which tools participating centers use (MAAC (Multi-Array Ablation Catheter) and/or MASC (Multi-Array Septal Catheter) and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
        <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
        <population>Persistent AF patients only</population>
        <group_list>
          <group group_id="O1">
            <title>Phased RFA System</title>
            <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Catheter PVAC (Pulmonary Vein Ablation Catheter) GOLD Utilization in Persistent AF Ablation - Percentage of Catheters Used Per Participant Procedure</title>
          <description>Evaluate which tools participating centers use (MAAC (Multi-Array Ablation Catheter) and/or MASC (Multi-Array Septal Catheter) and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
          <population>Persistent AF patients only</population>
          <units>percentage of patient procedures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phased RFA catheters used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAAC catheters used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MASC catheters used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other catheters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) including their relatedness to the respective procedure, were documented starting from the first documented procedure until the 12-month FU (follow-up). Analysis was performed at 30 days and 12 months after procedure.</time_frame>
      <desc>For the analysis, only adjudicated Adverse Event (AE) data and coded AE data (from free text fields) were used. In addition, TIA (transient ischaemic attack)/stroke events were taken from from the general follow-up forms to calculate procedure safety.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phased RFA System</title>
          <description>Observation study / registry with one patient group. Data on the use of the Phased AF system in the &quot;real world&quot; clinical practice / daily routine of EP laboratories utilizing the Phased AF system was collected.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1071"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Other diagnosis</sub_title>
                <description>Classified as other</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Left Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Phrenic Nerve Damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1071"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="1071"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Access Complication</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Other (diagnosis)</sub_title>
                <description>Other</description>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Left Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Pulmonary Vein (PV) Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack (TIA)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1071"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1071"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Details are described in the project specific Publication Plan.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ralf Meyer</name_or_title>
      <organization>Medtronic GmbH</organization>
      <phone>01755810431</phone>
      <email>ralf.meyer@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

